Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using a micro-organism to make a protein or polypeptide
Reexamination Certificate
2006-12-12
2006-12-12
Kam, Chih-Min (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using a micro-organism to make a protein or polypeptide
C435S252700, C435S253600, C435S842000, C424S236100, C424S239100
Reexamination Certificate
active
07148041
ABSTRACT:
Media and processes for the fermentation ofClostridium botulinumand obtaining abotulinumtoxin for use in formulatingbotulinumtoxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.
REFERENCES:
patent: 6558926 (2003-05-01), Demain et al.
patent: 2003/0118598 (2003-06-01), Hunt et al.
patent: 2005/0069562 (2005-03-01), Donovan
patent: WO 94/09115 (1993-10-01), None
patent: WO 98/54296 (1998-05-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01-36655 (2000-10-01), None
patent: WO 01/58472 (2001-02-01), None
Naumann, M., et al.,botulinumtoxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,Euro. J. Neurology1999:6(Suppl 4):S111-S115.
Porfirio, Z., et al., Specific peptides of casein pancreatic digestion enhance the production of tetanus toxin,J. of Applied Microbiology, 1997 83:678-684.
Ragona, Rosario Marchese, et al., Management of Parotid Sialocele withbotulinumtoxin,The Laryngoscope, 109:Aug. 1999:pp. 1344-1346.
Siegel, L.S., Fermentation kinetics ofbotulinumtoxin production (types A, B and E),Biomedical aspects of botulism, New York: Academic Press 1981: pp. 121-128.
Schantz, E.J., et al., Preparation and characterization ofbotulinumtoxin type A for human treatment, Jankovic J, ed.;Neurological Disease and Therapy. Therapy withBotulinum Toxin, 1994;25:pp. 41-49.
Schantz, E.J., et al., Properties and use ofbotulinumtoxin and other microbial neurotoxins in medicine,Microbiological Reviews, Mar. 1992, p. 80-99.
Schiefer-Ullrich, H., et al., Comparative studies on physiology and taxonomy of obligatory purinolytic clostridia,Arch Microbiol, 1984, 138:345-353.
Whitmer, M.E., et al., Development of improved defined media forClostridium botulinumserotypes A, B and E,Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, p. 753-759.
Coligan, et al.,Current protocols in protein science, Front Matter, Aug. 2003.
Lungdahl, L.G., et al., Working with anaerobic bacteria,Manual of Industrial Microbiology and Biotechnology, Chp. 8, 1986, pp. 84-96.
Mueller, J.H., et al., Variable factors influencing the product of tetanus toxin,J. Bacteriol, 1954; 67:271-7.
Ozutsumi, K., et al., Rapid, simplified method for production and purification of tetanus toxin,Applied and Environmental Microbiology, Apr. 1985, vol. 49, No. 4, pp. 939-943.
Chp. 1, pp. 1-88, Strategies of Protein Purification and Characterization,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed, Chp. 21, pp. 1-282.
Chp. 21, pp. 1-282, Peptidases,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed.
Bonventre, P.F. et al., Physiology of toxin production byClostridium botulinumtypes A and B,College of Medicine, vol. 7, pp. 372-374, (1959).
Chen, F., et al., Biophysical characterization of the stability of the 150-kilodaltonbotulinumtoxin, the nontoxic component and the 900-kilodaltonbotulinumtoxin complex species,Infect ImmunJun. 1998;66(6):2420-2425.
Holdeman, L., et al., A study of the nutritional requirements and toxin production ofClostridium botulinumtype F,Canadian Journal of Microbiology, vol. 11, (1965), pp. 1009-1019.
Johnson, E., et al.,Clostridium botulinumand its neurotoxins: a metabolic and cellular perspective,Toxicon39 (2001) 1703-1722.
Karasawa, T., et al., A defined growth medium forClostridium difficle,Microbiology(1995),141,371-375.
Kohl, A., et al., Comparison of the effect ofbotulinumtoxin A (BOTOX®) with the highly-purified neurotoxin (NT201) n the extensor digitorum brevis muscle test,MOV DISORD, 2000;15(Suppl 3):165.
Lewis, K.H., et al., Practical media and control measures for highly toxic cultures ofClostridium botulinumtype A,Production of botulinum Toxin, pp. 213-230, (1947).
Li, Y., et al., Expression and characterization of the heavy chain of tetanus toxin reconstitution of the fully-recombinant dichain protein in active form,J Biochem(Tokyo) Jun. 1999;125(6):1200-1208.
Heenan, C. N., et al., Lehensm.-Wiss. U.-Technol, 35 (2002), pp. 171-176.
Miwa, Norinaga, et al., International Journal of Food Microbiology, 49 (1999), pp. 103-106.
Mueller, J. H., et al., J. Bacteriology, Mar. 1954 67(3), pp. 271-277.
Whitmer, M. E., et al., Applid and Environmental Microbiology, Mar. 1988, 54(3), pp. 753-759.
Oxoid—Product CM0149—product description, pp. 1-2, (2004).
Allergan Inc.
Donovan Stephen
Kam Chih-Min
LandOfFree
Animal product free media and processes for obtaining a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Animal product free media and processes for obtaining a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Animal product free media and processes for obtaining a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678731